SGHT logo

Sight Sciences, Inc. (SGHT)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Sight Sciences, Inc. (SGHT) trades at $4.00 with AI Score 50/100 (Hold). Sight Sciences, Inc. is an ophthalmic medical device company focused on surgical and nonsurgical technologies for treating eye diseases. Market cap: 217M, Sector: Healthcare.

Last analyzed: Feb 8, 2026
Sight Sciences, Inc. is an ophthalmic medical device company focused on surgical and nonsurgical technologies for treating eye diseases. Their key products include the OMNI Surgical System for glaucoma and the TearCare System for dry eye disease.
50/100 AI Score Target $9.50 (+137.5%) MCap 217M Vol 190K

Sight Sciences, Inc. (SGHT) Healthcare & Pipeline Overview

CEOPaul Badawi
Employees216
HeadquartersMenlo Park, CA, US
IPO Year2021

Sight Sciences offers innovative solutions for glaucoma and dry eye, positioning itself for growth in the expanding ophthalmic device market. With proprietary technologies like OMNI and TearCare, SGHT aims to improve patient outcomes and capture market share in a high-demand sector.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 8, 2026

Investment Thesis

Sight Sciences presents a notable research candidate due to its innovative product portfolio addressing significant unmet needs in the ophthalmic market. The company's OMNI Surgical System and TearCare System target glaucoma and dry eye disease, respectively, both large and growing markets. The company's high gross margin of 86.0% indicates strong pricing power and potential for profitability as the company scales. Upcoming catalysts include continued expansion of the OMNI Surgical System in the glaucoma market and increased adoption of the TearCare System among optometrists and ophthalmologists. As Sight Sciences continues to penetrate these markets and drive revenue growth, the company's valuation should reflect its long-term potential.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market Cap of $0.31B reflects the company's current valuation in the ophthalmic device market.
  • Gross Margin of 86.0% demonstrates strong pricing power and efficient cost management.
  • P/E Ratio of -6.67 indicates that the company is currently not profitable, reflecting its growth stage and investments in R&D and commercialization.
  • Beta of 2.40 suggests higher volatility compared to the overall market, typical for growth-oriented medical device companies.
  • The company focuses on two major markets: glaucoma and dry eye disease, both with significant growth potential.

Competitors & Peers

Strengths

  • Innovative product portfolio addressing large markets (glaucoma and dry eye).
  • High gross margins (86.0%) indicating strong pricing power.
  • Focus on minimally invasive surgical and non-surgical solutions.
  • Direct sales force and established distribution network.

Weaknesses

  • Currently unprofitable, with a negative P/E ratio.
  • High beta (2.40) indicating higher volatility.
  • Reliance on a limited number of key products.
  • Relatively small market capitalization compared to larger competitors.

Catalysts

  • Ongoing: Continued expansion of OMNI Surgical System in the glaucoma market.
  • Ongoing: Increased adoption of TearCare System among optometrists and ophthalmologists.
  • Upcoming: Potential positive clinical trial results for new applications of existing technologies.
  • Upcoming: Expansion into new international markets.

Risks

  • Potential: Competition from larger, more established medical device companies.
  • Potential: Changes in reimbursement policies that could impact product pricing.
  • Ongoing: The company's current lack of profitability.
  • Potential: Product liability claims related to surgical devices.
  • Potential: Slower than expected adoption of new technologies.

Growth Opportunities

  • Expansion of OMNI Surgical System in Glaucoma Market: The global glaucoma market is projected to reach billions of dollars by 2028. Sight Sciences can capitalize on this growth by expanding the OMNI Surgical System's adoption among ophthalmic surgeons. This involves increasing awareness of the device's benefits, providing comprehensive training, and securing favorable reimbursement policies. The timeline for this expansion is ongoing, with continuous efforts to penetrate new markets and increase market share.
  • Increased Adoption of TearCare System for Dry Eye Disease: The dry eye disease (DED) market is a large and growing segment, driven by factors such as increased screen time and environmental conditions. Sight Sciences can drive adoption of the TearCare System by targeting optometrists and ophthalmologists. This includes demonstrating the system's efficacy, ease of use, and patient satisfaction. The timeline for increased adoption is expected over the next 3-5 years, as awareness and clinical data support its use.
  • Development of New Ophthalmic Technologies: Sight Sciences can invest in research and development to create new technologies and expand its product portfolio. This includes exploring new applications for existing technologies and developing novel solutions for other eye diseases. The timeline for new product development is typically 3-5 years, with ongoing research and clinical trials required to validate new innovations.
  • Strategic Partnerships and Acquisitions: Sight Sciences can pursue strategic partnerships and acquisitions to expand its market reach and product offerings. This includes collaborating with other companies in the ophthalmic space and acquiring complementary technologies. The timeline for partnerships and acquisitions is variable, depending on market opportunities and strategic alignment.
  • International Expansion: Sight Sciences can expand its operations into international markets to tap into new customer bases and revenue streams. This involves securing regulatory approvals, establishing distribution networks, and adapting its products to local market needs. The timeline for international expansion is typically 2-3 years per market, with careful planning and execution required to ensure success.

Opportunities

  • Expansion into international markets.
  • Development of new ophthalmic technologies and applications.
  • Strategic partnerships and acquisitions to broaden product offerings.
  • Increased adoption of TearCare System among optometrists.

Threats

  • Competition from established medical device companies.
  • Changes in reimbursement policies and healthcare regulations.
  • Potential for product liability claims.
  • Technological obsolescence and the emergence of new treatment modalities.

Competitive Advantages

  • Proprietary Technology: Patented OMNI Surgical System and TearCare System.
  • Established Relationships: Strong relationships with ophthalmic surgeons and optometrists.
  • High Gross Margins: Demonstrates pricing power and product differentiation.
  • Focus on Minimally Invasive Solutions: Addresses growing demand for less invasive procedures.

About SGHT

Sight Sciences, Inc., founded in 2010 and headquartered in Menlo Park, California, is dedicated to transforming the treatment of eye diseases through innovative surgical and nonsurgical technologies. The company's mission is to develop and commercialize solutions that address significant unmet needs in ophthalmology. Their flagship products include the OMNI Surgical System and the TearCare System. The OMNI Surgical System is a therapeutic device utilized by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients. This minimally invasive surgery (MIS) device allows surgeons to target multiple points of resistance in the conventional outflow pathway. The TearCare System is a wearable eyelid technology designed for the treatment of dry eye disease (DED). This system delivers targeted heat to the meibomian glands, improving gland function and relieving dry eye symptoms. Sight Sciences markets its products directly through sales representatives and through distributors to hospitals, medical centers, and eyecare professionals across the United States. The company's focus on innovation, combined with a direct sales approach, allows it to maintain close relationships with physicians and respond effectively to market needs. With a gross margin of 86.0%, Sight Sciences demonstrates the value and pricing power of its differentiated technologies.

What They Do

  • Develops and commercializes surgical technologies for glaucoma treatment.
  • Offers the OMNI Surgical System to reduce intraocular pressure in glaucoma patients.
  • Provides the TearCare System, a wearable eyelid technology for dry eye disease.
  • Markets products to hospitals, medical centers, and eyecare professionals.
  • Focuses on minimally invasive solutions for ophthalmic conditions.
  • Addresses unmet needs in the treatment of eye diseases.

Business Model

  • Sells OMNI Surgical System and TearCare System to medical facilities.
  • Generates revenue through direct sales representatives and distributors.
  • Focuses on recurring revenue through consumable products associated with the TearCare System.

Industry Context

Sight Sciences operates in the medical device industry, specifically within the ophthalmic segment. This segment is characterized by ongoing innovation and increasing demand due to the aging global population and rising prevalence of eye diseases. The market for glaucoma and dry eye treatments is substantial, with significant growth projected over the next decade. Sight Sciences competes with established players and smaller, specialized companies. The company differentiates itself through its proprietary technologies and focus on minimally invasive solutions. The competitive landscape includes companies like CERS, CVRX, LFCR, MASS, and OMI, each with varying approaches to treating ophthalmic conditions.

Key Customers

  • Ophthalmic surgeons who treat glaucoma patients.
  • Optometrists and ophthalmologists treating dry eye disease.
  • Hospitals and medical centers offering ophthalmic procedures.
  • Patients suffering from glaucoma and dry eye disease.
AI Confidence: 71% Updated: Feb 8, 2026

Financials

Chart & Info

Sight Sciences, Inc. (SGHT) stock price: $4.00 (-0.04, -0.99%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SGHT.

Price Targets

Consensus target: $9.50

MoonshotScore

50/100

What does this score mean?

The MoonshotScore rates SGHT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

SGHT Healthcare Stock FAQ

What does Sight Sciences, Inc. do?

Sight Sciences, Inc. is an ophthalmic medical device company that develops and commercializes surgical and nonsurgical technologies for the treatment of eye diseases. The company's primary products are the OMNI Surgical System, used to reduce intraocular pressure in glaucoma patients, and the TearCare System, a wearable eyelid technology for treating dry eye disease. Sight Sciences markets these products directly and through distributors to hospitals, medical centers, and eyecare professionals, focusing on innovative solutions to address unmet needs in ophthalmology.

Is SGHT stock worth researching?

SGHT stock presents a speculative investment opportunity with high growth potential. The company's innovative products, addressing large markets like glaucoma and dry eye, coupled with a high gross margin of 86.0%, suggest significant upside. However, the company is currently unprofitable, and the stock exhibits high volatility (beta of 2.40). Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing, weighing the growth potential against the inherent risks associated with a small-cap medical device company.

What are the main risks for SGHT?

The main risks for Sight Sciences include competition from larger, more established medical device companies, potential changes in reimbursement policies that could impact product pricing, and the company's current lack of profitability. Additionally, there are risks associated with product liability claims related to surgical devices and the potential for slower-than-expected adoption of new technologies. Investors should be aware of these risks and their potential impact on the company's financial performance and stock price.

What are the key factors to evaluate for SGHT?

Sight Sciences, Inc. (SGHT) currently holds an AI score of 50/100, indicating moderate score. Analysts target $9.50 (+138% from $4.00). Key strength: Innovative product portfolio addressing large markets (glaucoma and dry eye).. Primary risk to monitor: Potential: Competition from larger, more established medical device companies.. This is not financial advice.

How frequently does SGHT data refresh on this page?

SGHT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven SGHT's recent stock price performance?

Recent price movement in Sight Sciences, Inc. (SGHT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $9.50 implies 138% upside from here. Notable catalyst: Innovative product portfolio addressing large markets (glaucoma and dry eye).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider SGHT overvalued or undervalued right now?

Determining whether Sight Sciences, Inc. (SGHT) is overvalued or undervalued requires examining multiple metrics. Analysts target $9.50 (+138% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying SGHT?

Before investing in Sight Sciences, Inc. (SGHT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on the most recent available information.
  • Future performance is subject to market conditions and company-specific factors.
Data Sources

Popular Stocks